Cytiva expanded its collaboration with Culture Biosciences, which specializes in cloud-connected bioreactor technology, to include both hardware commercialization and technology development. Building ...
SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...
Still flying high on a $1.5 billion investment from its parent company, the Danaher Group, Cytiva has acquired a facility in Muskegon, Mich., which it will transform into a manufacturing site for ...
Cambridge, UK and Marlborough, MA, 28 May 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a ...
Cytiva, backed by a $1.5 billion investment from its parent company, the Danaher Group, continued its expansion tear with the acquisition of CEVEC Pharmaceuticals. CEVEC, which is based in Cologne, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results